BTG plc (BTG.L), the specialist healthcare company, announced that the New Drug Application or NDA seeking approval of Varisolve as a comprehensive treatment for varicose veins, which was submitted to the US Food & Drug Administration or FDA on February 4, 2013, has been accepted for full review by the FDA.
Based on standard review timelines, BTG expects potential US approval and launch of PEM during the first half of 2014.
For comments and feedback: editorial@rttnews.com